Adhesive device

Abstract

An adhesive device (1) comprising a base sheet (11) having a first surface (11A) and a second surface (11B), a drug-containing resin layer (21) provided to the first surface (11A) of the base sheet (11), and a moisture-retaining portion (31) provided to the first surface (11A) of the base sheet (11), wherein the drug-containing resin layer (21) and the moisture-retaining portion (31) are arranged on the base sheet (11) such that the drug-containing resin layer (21) overlaps the moisture-retaining portion (31) by folding back the base sheet (11) between the drug-containing resin layer (21) and the moisture-retaining portion (31), with the first surface (11A) facing inward.

Description

Patch device

[0001] The present disclosure relates to a patch device, and more specifically to a patch device used by being attached to the skin.

[0002] Conventionally, patch devices used by being attached to the skin are known. Patch devices are used for purposes such as medication administration, anesthesia, analgesia, anti-inflammation, and beauty care, for example. Since patch devices can percutaneously provide medicinal and active ingredients, they have the advantages of being non-invasive, imposing less burden on users, and ensuring sustained administration.

[0003] As adhesive devices, for example, Patent Document 1 discloses a thermal cosmetic sheet, Patent Document 2 discloses a sheet-shaped face pack, Patent Document 3 discloses a gel sheet for packs, and Patent Document 4 discloses an adhesive patch. Specifically, Patent Document 1 discloses a package for a thermal cosmetic sheet in which a sheet-shaped heating element and a sheet-shaped cosmetic are separately contained, and the package has a fold line between the sheet-shaped heating element and the sheet-shaped cosmetic, and is arranged so that the sheet-shaped heating element and the sheet-shaped cosmetic overlap when folded in half along the fold line. Patent Document 2 discloses a sheet storage device having a first outer casing, a second outer casing, and a partition body disposed between them, the partition body dividing the interior into multiple regions, a sealing portion sealing the periphery of the first outer casing, the second outer casing, and the partition body, a plurality of sheets housed in each of the multiple regions, and cutting portions engraved on each of the first outer casing, the second outer casing, and the partition body. Patent Document 3 discloses a pack gel sheet packaging body having a tray consisting of a dish-shaped recess, a storage recess formed at the bottom of the tray for housing a pack gel sheet, and a liquid reservoir recess formed at the bottom of the storage recess for housing a beauty serum, the pack gel sheet packaging body packaging the pack gel sheet and the tray. Patent Document 4 discloses an adhesive patch comprising a support, an adhesive efficacy composition laminated on the surface of the support, and a sheet-like peel-off protective member peelably attached to the outer surface of the efficacy composition, wherein the peel-off protective member consists of a plurality of segmented peel-off pieces, the plurality of segmented peel-off pieces are separated and arranged adjacent to each other with a groove-shaped bending gap as the boundary, and the peel-off protective member is configured to be foldable with the bending gap as the crease.

[0004] Japanese Patent Publication No. 2010-053061, Japanese Patent Publication No. 2017-197269, Japanese Patent Publication No. 2006-056543, Japanese Patent Publication No. 2023-070505

[0005] When a patch device is applied to the skin, it is desirable that the penetration of the medicinal or active ingredient into the skin is ensured as much as possible, thereby enhancing the efficacy of the patch device. The problem to be solved by this disclosure is to provide a patch device that can enhance the penetration of drugs from the drug-containing resin layer into the skin through simple operation.

[0006] The adhesive devices according to this disclosure that have been able to solve the aforementioned problems are as follows: [1] An adhesive device comprising a base sheet having a first surface and a second surface, a drug-containing resin layer provided on the first surface of the base sheet, and a moisture-retaining portion provided on the first surface of the base sheet, wherein the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet such that the drug-containing resin layer overlaps the moisture-retaining portion by folding the base sheet with the first surface facing inward between the drug-containing resin layer and the moisture-retaining portion. [2] The adhesive device according to [1], wherein the surface of the drug-containing resin layer opposite to the base sheet is adhesive. [3] The adhesive device according to [1] or [2], wherein the surface of the drug-containing resin layer opposite to the base sheet has a hydrophobic region. [4] The adhesive device according to [3], further comprising a water-permeable sheet peelably bonded to the surface of the drug-containing resin layer opposite to the base sheet. [5] The adhesive device according to [4], wherein the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet by folding the base sheet with the first surface facing inward between the drug-containing resin layer and the moisture-retaining portion so that the water-permeable sheet overlaps the moisture-retaining portion. [6] The adhesive device according to [4] or [5], further comprising a release sheet, wherein the release sheet is provided to cover at least one of the water-permeable sheet and the moisture-retaining portion. [7] The adhesive device according to any one of [1] to [6], wherein a valley fold line is formed on the first surface of the base sheet, and the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet by folding the base sheet with the first surface facing inward along the valley fold line so that the drug-containing resin layer overlaps the moisture-retaining portion. [8] The adhesive device according to any one of [1] to [6], wherein perforations are formed on the first surface of the base sheet, and the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet such that the drug-containing resin layer overlaps the moisture-retaining portion when the base sheet is folded back along the perforations with the first surface facing inward. [9] The adhesive device according to any one of [1] to [8], wherein a support layer is provided on the base sheet side of the drug-containing resin layer, and the support layer is peelably attached to the base sheet.

[10] An adhesive device according to any one of [1] to [9], wherein a recess is provided on the first surface of the base sheet, and the moisture-retaining portion is disposed in the recess.

[11] An adhesive device according to any one of [1] to

[10] , wherein the size of the drug-containing resin layer is smaller than the size of the moisture-retaining portion.

[12] An adhesive device according to any one of [1] to

[11] , wherein a support layer is provided on the base sheet side of the drug-containing resin layer, the support layer is peelably attached to the base sheet, a recess is provided on the first surface of the base sheet, the moisture-retaining portion and a temporary fixing portion of the drug-containing resin layer are provided in the recess, at least a part of the periphery of the moisture-retaining portion are provided, and the upper surface of the temporary fixing portion is lower than the upper surface of the moisture-retaining portion by 1 / 2 or less of the thickness of the moisture-retaining portion.

[13] An adhesive device according to any one of [1] to

[12] , wherein a pressing portion is formed on the base sheet that can be pressed from the second surface side to the first surface side, and the drug-containing resin layer is disposed in the pressing portion.

[14] The adhesive device according to any one of [1] to

[13] , wherein the moisture-retaining portion is a porous body that retains moisture or a fiber aggregate that retains moisture.

[15] The adhesive device according to any one of [1] to

[14] , further comprising a release sheet laminated on the base sheet so as to cover the drug-containing resin layer and the moisture-retaining portion on the first surface side of the base sheet, wherein the release sheet is peelably bonded to the base sheet.

[16] The adhesive device according to any one of [1] to

[15] , wherein the first surface of the base sheet is divided into a first region and a second region, the drug-containing resin layer is provided in the first region, the moisture-retaining portion is provided in the second region, a first engagement portion is provided in the first region of the base sheet, and a second engagement portion is provided in the second region of the base sheet, and the first engagement portion and the second engagement portion are arranged on the base sheet so as to be able to engage with each other by folding the base sheet with the first surface facing inward so that the drug-containing resin layer overlaps the moisture-retaining portion.

[17] The adhesive device according to

[16] , wherein the first engaging portion and the second engaging portion are a combination of a convex portion and a concave portion formed on the first surface of the base sheet.

[0007] The adhesive device according to this disclosure allows moisture to adhere to the drug-containing resin layer by folding the base sheet with the first surface facing inward between the drug-containing resin layer and the moisture-retaining portion. Subsequently, the adhesive device can be attached to the skin by bringing the drug-containing resin layer into contact with the skin. When the adhesive device is attached in this way, the moisture adhering to the drug-containing resin layer adheres to the skin surface, softening and supple the skin surface with moisture. As a result, the adhesion of the drug-containing resin layer to the skin surface is enhanced, and the penetration of the drug from the drug-containing resin layer into the skin can be improved. Furthermore, moisture can be supplied to the drug-containing resin layer with simple operation, resulting in an easy-to-handle adhesive device.

[0008] Figure 1 shows an example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 1 shows a plan view of the adhesive device shown in Figure 1, viewed from above. Figure 1 shows a cross-sectional view of the adhesive device shown in Figure 1, folded back. Figure 5 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 5 shows a plan view of the adhesive device shown in Figure 5, viewed from above. Figure 5 shows a cross-sectional view of the adhesive device shown in Figure 5, folded back. Figure 6 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 7 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 8 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 9 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. Figure 10 shows another example of the configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. This shows another example configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. This shows another example configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. This shows another example configuration of the adhesive device according to this disclosure, and a cross-sectional view of the adhesive device. This shows a plan view of the adhesive device shown in Figure 16, viewed from above.

[0009] The contents of this disclosure will be described in detail below based on the embodiments described below. However, the contents of this disclosure are not limited by the embodiments described below, and it is certainly possible to implement the disclosure with appropriate modifications to the extent that it is in line with the spirit of the preceding and following descriptions, and all such modifications are included within the technical scope of this disclosure. In addition, hatching and component reference numerals may be omitted in the drawings for convenience, in which case refer to the specification or other drawings. Furthermore, the dimensions of various components in the drawings may differ from the actual dimensions, as priority is given to helping to understand the features of this disclosure.

[0010] An example of the configuration of the adhesive device according to the embodiment of the present disclosure will be described with reference to Figures 1 to 3. Figure 1 shows a cross-sectional view of one embodiment of the adhesive device of the present disclosure, Figure 2 shows a plan view of the adhesive device shown in Figure 1, and Figure 3 shows a cross-sectional view of the adhesive device shown in Figure 1 in a folded state.

[0011] The adhesive device 1 according to the embodiment of this disclosure comprises a base sheet 11 having a first surface 11A and a second surface 11B, and a drug-containing resin layer 21 and a moisture-retaining portion 31 provided on the first surface 11A of the base sheet 11. The adhesive device 1 is used by being attached to the skin and is a device that can deliver drugs transdermally.

[0012] The adhesive device 1 has a planar direction in which the base sheet 11 extends, and a thickness direction perpendicular to the planar direction. An upper and lower side are defined with respect to the thickness direction; the upper side is the side that faces the skin (epithelial tissue) when the adhesive device 1 is placed on the skin and used, and the lower side is the opposite side.

[0013] The base sheet 11 is a sheet on which a drug-containing resin layer 21 and a moisture-retaining portion 31 are arranged. The base sheet 11 has a first surface 11A and a second surface 11B opposite to the first surface 11A, with the drug-containing resin layer 21 and the moisture-retaining portion 31 arranged on the first surface 11A of the base sheet 11. Both the first surface 11A and the second surface 11B are the main surfaces of the base sheet 11, with the first surface 11A being the upper surface of the base sheet 11 and the second surface 11B being the lower surface of the base sheet 11.

[0014] The material of the base sheet 11 is not particularly limited and can be appropriately selected depending on the purpose. Examples of materials that can be used as the base sheet 11 include resin films formed from polyolefins (e.g., polyethylene, polypropylene), polyesters (e.g., polyethylene terephthalate), polyamides (e.g., nylon 6), polycarbonate, polyvinyl alcohol, ethylene-vinyl alcohol copolymer, polyvinyl chloride, polyvinylidene chloride, polystyrene, cellulose, acrylic resin, etc.; aluminum foil or aluminum film; foamed resin films such as foamed polyethylene film or foamed polypropylene film; and paper such as glassine paper. These may be used individually or in combination. The base sheet 11 may or may not be stretchable.

[0015] The shape (planar shape) of the base sheet 11 is not particularly limited and can include polygons such as squares, hexagons, and octagons, polygons with rounded corners, circles, ellipses, dumbbell shapes, and irregular shapes.

[0016] The thickness of the base sheet 11 may be, for example, 0.05 mm or more, or 0.1 mm or more, or it may be 3.0 mm or less, 2.0 mm or less, or 1.0 mm or less.

[0017] The drug-containing resin layer 21 and the moisture-retaining portion 31 are provided in different areas of the first surface 11A of the base sheet 11. For example, the first surface 11A of the base sheet 11 is divided into a first region 12 and a second region 13, with the drug-containing resin layer 21 provided in the first region 12 and the moisture-retaining portion 31 provided in the second region 13.

[0018] The drug-containing resin layer 21 contains at least a drug and a resin. In the drug-containing resin layer 21, it is preferable that the drug is dispersed in the resin. The drug may be uniformly or non-uniformly distributed in the resin. For example, the drug may be distributed in the resin such that areas with high and low drug concentrations are formed.

[0019] Examples of drugs include low molecular weight compounds, peptides, proteins, high molecular weight compounds such as oligonucleotides, antibody drugs, and nucleic acid drugs. The drug compound preferably has an ionizing group, which, as described later, promotes the release of the drug from the drug-containing resin layer 21 and facilitates the penetration of the drug into the skin when the drug-containing resin layer 21 is brought into contact with the moisture-retaining portion 31 to provide moisture to the surface of the drug-containing resin layer 21 and applied to the skin. Examples of ionizing groups include amino groups, carboxyl groups, sulfonic acid groups, and phosphate groups, and these ionizing groups may exist in the form of pharmaceutically acceptable salts. The drug compound also preferably has an aromatic group, which facilitates the presence of the drug in the resin at high concentrations. The aromatic group is more preferably an aromatic hydrocarbon group.

[0020] The drug contained in the drug-containing resin layer 21 is preferably a pharmaceutical product. Examples of drugs include anti-inflammatory and analgesic agents such as acetaminophen, phenacetin, mefenamic acid, diclofenac sodium, flufenamic acid, aspirin, sodium salicylate, methyl salicylate, glycol salicylate, aminopyrine, alclofenac, ibuprofen, naproxen, flurbiprofen, ketoprofen, amfenac sodium, mepirizole, indomethacin, piroxicam, and felbinac; steroidal anti-inflammatory agents such as hydrocortisone, triamcinolone, dexamethasone, and prednisolone; and hydrochloric acid. Vasodilators such as diltiazem, pentaerythritol tetranitrate, isosorbide dinitrate, tarajipil, nicorandil, nitroglycerin, preniramine lactate, morcidomin, amyl nitrite, trazoline hydrochloride, and nifedipine; antiarrhythmic agents such as procainamide hydrochloride, lidocaine hydrochloride, propranolol hydrochloride, alprenolol hydrochloride, atenolol, nadolol, metoprolol tartrate, ajmaline, disopyramide, and mexiletine hydrochloride; ecalazine hydrochloride, indapamide, clonidine hydrochloride, bnitrolol hydrochloride, labetalol hydrochloride, and captopurisine hydrochloride. Antihypertensive agents such as guanabenz acetate, mebutamate, and betanidine sulfate; antihypertensive agents such as carbetapentane citrate, cloperastin, oxerazine tannate, clobutinol hydrochloride, clofedanol hydrochloride, noscapine hydrochloride, ephedrine hydrochloride, isoproterenol hydrochloride, chloriprenaline hydrochloride, methoxyphenamine hydrochloride, procaterol hydrochloride, tulobuterol hydrochloride, clenputerol hydrochloride, and ketotifen fumarate; and antiseptics such as cyclophosphamide, fluorouracil, degafur, mitomycin C, procarbazine hydrochloride, and doxif Antineoplastic agents such as rulizine and ranimustine; local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, brocaine hydrochloride, dibucaine hydrochloride, oxybuprocaine hydrochloride, and propitocaine hydrochloride; hormonal agents such as propylthiouracil, thiamazole, meteronone acetate, estradiol, estriol, and progesterone; antihistamines such as diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diproheptadine hydrochloride, and diphenylpyraline hydrochloride; anticoagulants such as warfarin potassium and ticlopidine hydrochloride;Antispasmodics such as methylatropine bromide and scopolamine; general anesthetics such as thiopental sodium and pentobarbital sodium; hypnotics and analgesics such as bromwarenylurea, amobarbital, and phenobarbital; antiepileptics such as phenytoin sodium; stimulants and aphrodisiacs such as methamphetamine hydrochloride; sedatives such as difendol hydrochloride and betahistine mesylate; chlorpromazine hydrochloride, thioridazine, meprobamate, imipramine hydrochloride, chlordiazepoxide, diazepam, risperidone, and paliperidone. Psychotropic agents such as olanzapine, aripiprazole, paroxetine, and duloxetine; skeletal muscle relaxants such as succinylcholine hydrochloride and eperisone hydrochloride; autonomic nervous system agents such as neostigmine bromide and bethanechol chloride; antiparkinsonian agents such as amantadine hydrochloride, rotigotine, and ropinirole; anti-Alzheimer's disease drugs such as donepezil, galantamine, memantine, and rivastigmine; diuretics such as hydroflumethiazide, isosorbide, and furosemide; vasoconstrictors such as phenylephrine hydrochloride; loberine bromide, dimol Respiratory stimulants such as holamine and naloxone hydrochloride; peptic ulcer treatments such as glycopyrronium bromide, proglumide, cetraxate hydrochloride, cimetidine, and spizoflon; cholagogues such as ursodeoxycholic acid and osalmid; urogenital and anal preparations such as hexamine, spartin, dinoprost, ritodrine hydrochloride, oxybutynin, tolterodine, solifenacin, and dalifenacin; parasitic skin disease treatments such as salicylic acid, cyclopiroxolamine, and coloconazole hydrochloride; emollients such as urea; calcitriol Vitamin preparations such as thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride, nicotinamide, panthenol, and ascorbic acid; inorganic preparations such as calcium chloride, potassium iodide, and sodium iodide; hemostatic agents such as ethanesylates; liver disease agents such as thiopronin; habitual poisoning agents such as cyanamide; gout treatment agents such as colchicine, probenecid, and sulfinpyrazone; antidiabetic agents such as tolbutamide, chlorpropamide, glimidine sodium, glypsol, buformin hydrochloride, and insulin;Examples include antibiotics such as benzylpenicillin potassium, propicillin potassium, cloxacillin sodium, ampicillin sodium, bacampyricin hydrochloride, carbenicillin sodium, cephalolidine, cefoxitin sodium, erythromycin, chloramphenicol, tetracycline, kanamycin sulfate, and cycloserine; chemocytogenic agents such as isocyanides, pyrazinamide, and ethionamide; and narcotics such as morphine hydrochloride, codeine phosphate, cocaine hydrochloride, pethidine hydrochloride, and fentanyl citrate.

[0021] Examples of resins that form the drug-containing resin layer 21 include fluorine-based resins such as polytetrafluoroethylene (PTFE), acrylic resins such as octyl acrylate copolymers, silicone resins, polyester resins, styrene-based thermoplastic elastomers such as styrene-isoprene-styrene block copolymers, vinyl chloride resins, polyolefin resins, acrylic acid copolymers, polyethylene glycol, vinyl polymers such as polyvinyl alcohol and polyvinylpyrrolidone, and cellulose derivatives.

[0022] The drug-containing resin layer 21 may contain a tackifier. Known tackifiers can be used. The drug-containing resin layer 21 may also contain additives such as plasticizers, drug solvents, permeation enhancers, crystal precipitation inhibitors, excipients, antioxidants, tackifiers, fragrances, colorants, etc.

[0023] The thickness of the drug-containing resin layer 21 may be, for example, 0.01 mm or more, or 0.05 mm or more, or it may be 2.0 mm or less, 1.5 mm or less, or 1.2 mm or less.

[0024] The moisture-retaining portion 31 contains at least moisture. Moisture is retained in the moisture-retaining portion 31, and when the adhesive device 1 is used, the moisture retained in the moisture-retaining portion 31 is attached to the upper surface 21A of the drug-containing resin layer 21. Preferably, the moisture includes at least water such as tap water, purified water, distilled water, sterile purified water, or water for injection. In addition to water, the moisture may also contain additives such as sodium chloride, ethanol, or glycerin. Examples of substances containing sodium chloride in addition to water include saline solution and physiological saline solution, examples of substances containing ethanol in addition to water include disinfectant or antiseptic solution, and examples of substances containing glycerin in addition to water include lotions.

[0025] The moisture-retaining portion 31 may contain only moisture, or it may contain moisture in a moisture-retaining member. Preferably, the moisture-retaining portion 31 contains moisture so that it can be brought into contact with the drug-containing resin layer 21 to provide moisture to the upper surface 21A of the drug-containing resin layer 21. Furthermore, it is preferable that moisture is stably retained in the moisture-retaining portion 31 before use of the adhesive device 1. From this viewpoint, it is preferable that the moisture-retaining portion 31 has a porous body that retains moisture or a fiber aggregate that retains moisture.

[0026] The porous material preferably has voids inside, and these voids are in communication with the outside of the porous material. For example, the porous material preferably contains air bubbles, and preferably has continuous air bubbles where the air bubbles are connected. The porous material preferably is elastically deformable, and a sponge is a suitable example of such a porous material, and the porous material is preferably composed of a resin. Examples of resins that constitute the porous material include polyurethane resins, fluororesins such as PTFE, PFA, and ETFE, polyolefin resins such as polyethylene and polypropylene, polyester resins such as polyethylene terephthalate and polybutylene terephthalate, silicone resins such as polydimethylsiloxane, polyamide resins such as nylon, and cellulose derivatives such as hydroxyethylcellulose and hydroxypropylcellulose.

[0027] Examples of fiber aggregates include nonwoven fabrics, woven fabrics, knitted fabrics, and other fabric materials, as well as fiber bundles. Fiber aggregates may also be felt or tow (fiber bundles). Fibers included in the fiber aggregates include natural fibers such as cotton, linen, and silk; regenerated fibers such as rayon; semi-synthetic fibers such as acetate; and synthetic fibers formed from polyester (e.g., PET), polyolefins (e.g., polypropylene, polyethylene), polyurethane, polyamide (e.g., nylon), acrylic, melamine, etc. It is preferable that the surface of the synthetic fibers is hydrophilized with a surfactant or the like. The basis weight of the fiber aggregate is, for example, 200 g / m². ２ Above, 300g / m ２ or more, or 400 g / m ２ It may be greater than or equal to 5000 g / m². ２ Below, 3500g / m ２ The following or 2500 g / m ２ The following is also acceptable.

[0028] The thickness of the moisture-retaining portion 31 may be, for example, 1 mm or more, 2 mm or more, or 10 mm or less, 9 mm or less, or 8 mm or less.

[0029] The drug-containing resin layer 21 and the moisture-retaining portion 31 are arranged on the base sheet 11 such that the drug-containing resin layer 21 overlaps the moisture-retaining portion 31 by folding the base sheet 11 with the first surface 11A facing inward between the drug-containing resin layer 21 and the moisture-retaining portion 31. Specifically, the base sheet 11 has a folded portion 14 at the boundary between the first region 12 and the second region 13, and the drug-containing resin layer 21 and the moisture-retaining portion 31 are arranged on the base sheet 11 such that the drug-containing resin layer 21 overlaps the moisture-retaining portion 31 by folding the base sheet 11 at the folded portion 14 with the first surface 11A facing inward. As shown in Figure 3, when the base sheet 11 is folded over at the folded portion 14 between the drug-containing resin layer 21 and the moisture-retaining portion 31 with the first surface 11A facing inward, the drug-containing resin layer 21 can be placed on top of the moisture-retaining portion 31, and moisture can be attached to the upper surface 21A of the drug-containing resin layer 21.

[0030] The adhesive device 1 is attached to the skin by first applying moisture to the upper surface 21A of the drug-containing resin layer 21, and then bringing the upper surface 21A of the drug-containing resin layer 21 into contact with the skin. Specifically, after applying moisture to the upper surface 21A of the drug-containing resin layer 21, the fold at the folded portion 14 of the base sheet 11 is unfolded, and the drug-containing resin layer 21 is peeled off the base sheet 11, or the adhesive device 1 is attached to the skin together with the drug-containing resin layer 21 and the base sheet 11. The upper surface 21A of the drug-containing resin layer 21 becomes the adhesive surface. When the adhesive device 1 is attached in this way, the moisture attached to the upper surface 21A of the drug-containing resin layer 21 adheres to the skin surface, and the skin surface covered by the drug-containing resin layer 21 becomes more susceptible to becoming soft and swollen due to the moisture. This increases the adhesion of the drug-containing resin layer 21 to the skin surface and improves the penetration of the drug from the drug-containing resin layer 21 into the skin.

[0031] The adhesive device 1 can easily supply moisture to the upper surface 21A of the drug-containing resin layer 21 by folding the base sheet 11 and overlapping the drug-containing resin layer 21 with the moisture-retaining portion 31. Therefore, moisture can be supplied to the upper surface 21A of the drug-containing resin layer 21 with simple operation, resulting in an easy-to-handle adhesive device 1.

[0032] The folded portion 14 of the base sheet 11 may or may not have a crease formed in advance. In the former case, it is preferable that a fold line is formed on the first surface 11A of the base sheet 11 at the folded portion 14. In the latter case, the folded portion 14 of the base sheet 11 may be provided with a mark indicating the position where the crease is to be formed, or the base sheet 11 may be formed with a thinner thickness at the folded portion 14, or the base sheet 11 may be formed with lower rigidity at the folded portion 14, or perforations may be formed on the folded portion 14 of the base sheet 11. Before use of the adhesive device 1, it is preferable that the base sheet 11 is not folded at the folded portion 14.

[0033] Preferably, the base sheet 11 has a valley fold line formed on its first surface 11A as a folded portion 14. That is, it is preferable that the base sheet 11 has a valley fold line formed on its first surface 11A, and that the drug-containing resin layer 21 and the moisture-retaining portion 31 are arranged on the base sheet 11 such that the drug-containing resin layer 21 overlaps the moisture-retaining portion 31 when the base sheet 11 is folded back along the valley fold line with the first surface 11A facing inward. The valley fold line of the base sheet 11 may also be a groove formed on the first surface 11A of the base sheet 11. By forming a valley fold line on the first surface 11A of the base sheet 11, it becomes easier to fold the base sheet 11 along the valley fold line when the first surface 11A is folded back with the first surface 11A facing inward, and it becomes easier to accurately overlap the moisture-retaining portion 31 with the drug-containing resin layer 21.

[0034] It is also preferable that the base sheet 11 has perforations formed as a fold-over portion 14. That is, it is preferable that perforations are formed on the first surface 11A of the base sheet 11, and the drug-containing resin layer 21 and the moisture-retaining portion 31 are arranged on the base sheet 11 such that the drug-containing resin layer 21 overlaps the moisture-retaining portion 31 when the base sheet 11 is folded back along the perforations with the first surface 11A inward. In this case as well, it becomes easier to fold the base sheet 11 back along the perforations when the first surface 11A is folded inward, and it becomes easier to accurately overlap the moisture-retaining portion 31 with the drug-containing resin layer 21.

[0035] The side of the drug-containing resin layer 21 opposite to the base sheet 11, i.e., the upper surface 21A of the drug-containing resin layer 21, is preferably adhesive. For the upper surface 21A of the drug-containing resin layer 21 to be adhesive, it is preferable that the resin contained in the drug-containing resin layer 21 is an elastomer resin. This improves the adhesion and conformability of the drug-containing resin layer 21 to the skin when the adhesive device 1 is attached to the skin, making it easier to transfer the drug from the drug-containing resin layer 21 to the skin surface.

[0036] The adhesive device 1, in which the upper surface 21A of the drug-containing resin layer 21 is adhesive, allows the drug-containing resin layer 21 to be peeled off the base sheet 11 and attached to the skin. In this case, as shown in Figures 4, 11 to 13, it is preferable that a support layer 22 is provided on the base sheet 11 side, i.e., the lower side, of the drug-containing resin layer 21, and that the support layer 22 is detachably attached to the base sheet 11. Figures 4, 11 to 13 show cross-sectional views of other embodiments of the adhesive device 1. The support layer 22 is handled integrally with the drug-containing resin layer 21. By peeling the drug-containing resin layer 21 together with the support layer 22 from the base sheet 11, the drug-containing resin layer 21 can be attached to the skin.

[0037] The type of support layer 22 is not particularly limited, and known types can be used. Examples of support layers 22 include stretchable or non-stretchable woven or nonwoven fabrics formed from polyethylene, polypropylene, polyester, etc.; films formed from polyethylene, polypropylene, ethylene vinyl acetate copolymer, vinyl chloride, polyurethane, etc.; and foamed supports formed from polyethylene, polyurethane, etc. These may be used individually or in combination. The support layer 22 may also be a nonwoven or woven fabric containing an antistatic agent to prevent static electricity buildup and to ensure good anchoring with the drug-containing resin layer 21. The support layer 22 may also be a release-processed material. Examples of release processing include applying a silicone resin to create a silicone resin layer (silicone processing).

[0038] When the support layer 22 is peelably attached to the base sheet 11, it is preferable that an adhesive portion is provided on the first surface 11A of the base sheet 11 overlapping with the support layer 22. This allows the support layer 22 to be peelably attached to the base sheet 11. In this case, the adhesive portion does not need to be provided in the area of ​​the first surface 11A of the base sheet 11 where the support layer 22 is not placed, thereby making it easier to peel the support layer 22 from the base sheet 11. The adhesive portion may be provided over the entire area of ​​the first surface 11A of the base sheet 11 where the support layer 22 is placed, or it may be provided only in a part of it. From the viewpoint of making it easier to peel the support layer 22 from the base sheet 11, it is preferable that, in a plan view of the attachment device 1, at least a part of the outer edge of the adhesive portion is located inward from the outer edge of the support layer 22, and it is more preferable that the entire outer edge of the adhesive portion is located inward from the outer edge of the support layer 22.

[0039] The adhesive device 1 may be used by attaching the drug-containing resin layer 21 to the skin together with the base sheet 11. The adhesive device 1 shown in Figures 1 to 3 can be used in this way, for example. In this case, it is preferable that an adhesive portion is provided around the drug-containing resin layer 21 on the first surface 11A of the base sheet 11. As a result, when the adhesive device 1 is attached to the skin, the base sheet 11 adheres to the skin so as to surround the drug-containing resin layer 21, and the skin surface on which the drug-containing resin layer 21 is placed becomes more susceptible to softening due to moisture. That is, moisture is applied from the moisture-retaining portion 31 to the upper surface 21A of the drug-containing resin layer 21, and furthermore, the moisture supplied to the skin surface from the upper surface 21A of the drug-containing resin layer 21 tends to remain between the drug-containing resin layer 21 and the skin without escaping from the base sheet 11, making the skin surface covered by the drug-containing resin layer 21 more susceptible to softening.

[0040] In the above case, a support layer 22 is not required to be provided on the underside of the drug-containing resin layer 21. The upper surface 21A of the drug-containing resin layer 21 may or may not be adhesive, but from the viewpoint of improving the adhesion of the drug-containing resin layer 21 to the skin, it is preferable that the upper surface 21A of the drug-containing resin layer 21 be adhesive.

[0041] When the patch device 1 is used by attaching the drug-containing resin layer 21 to the skin together with the base sheet 11, it is preferable that, on the first surface 11A of the base sheet 11, the first region 12 has an adhesive part and the second region 13 does not have an adhesive part. It is also preferable that the first region 12 is separated from the second region 13 and the patch device 1 is attached to the skin. This allows the moisture retaining part 31 to be separated, and the drug-containing resin layer 21 to be attached to the skin together with the base sheet 11. Therefore, in this case, it is preferable that a perforation is formed as the folded part 14 in the base sheet 11.

[0042] Even when the patch device 1 is used by peeling the drug-containing resin layer 21 from the base sheet 11 and attaching it to the skin, a perforation may be formed as the folded part 14 in the base sheet 11. The patch device 1 configured as described above can be used in the following manner: separating the base sheet 11 at the perforation of the folded part 14 to cut off the first region 12 from the second region 13, placing the drug-containing resin layer 21 on the skin together with the first region 12 of the base sheet 11 to attach the drug-containing resin layer 21 to the skin, and then peeling the first region 12 of the base sheet 11 from the drug-containing resin layer 21. This allows the patch device 1 to be attached to the skin without touching the drug-containing resin layer 21.

[0043] Preferably, the drug-containing resin layer 21 is provided to protrude on the first surface 11A of the base sheet 11. That is, it is preferable that the upper surface 21A of the drug-containing resin layer 21 is located above the first surface 11A of the base sheet 11 in the thickness direction. This facilitates peeling the drug-containing resin layer 21 from the base sheet 11 when the drug-containing resin layer 21 is peeled from the base sheet 11 and attached to the skin. When the drug-containing resin layer 21 is attached to the skin together with the base sheet 11, the adhesion of the drug-containing resin layer 21 to the skin is easily improved.

[0044] As one embodiment of the patch device 1, the size of the drug-containing resin layer 21 is preferably smaller than the size of the moisture retaining portion 31. Specifically, in a plan view of the patch device 1, the size of the drug-containing resin layer 21 is preferably smaller than the size of the moisture retaining portion 31. This makes it easy to bring the entire upper surface 21A of the drug-containing resin layer 21 into contact with the moisture retaining portion 31 when the drug-containing resin layer 21 is superimposed on the moisture retaining portion 31, and facilitates adhesion of moisture to a wide range of the upper surface 21A of the drug-containing resin layer 21.

[0045] The surface of the drug-containing resin layer 21 opposite to the base sheet 11, that is, the upper surface 21A of the drug-containing resin layer 21, preferably has a hydrophobic region. If a hydrophobic region is formed on the upper surface 21A of the drug-containing resin layer 21, applying moisture to the upper surface 21A of the drug-containing resin layer 21 and attaching the patch device 1 to the skin facilitates release of the drug from the drug-containing resin layer 21. For example, when the entire upper surface 21A of the drug-containing resin layer 21 is a hydrophilic region, even if moisture is adhered to the upper surface 21A of the drug-containing resin layer 21, the drug is not sufficiently distributed to the moisture side and tends to remain in the drug-containing resin layer 21; whereas if the upper surface 21A of the drug-containing resin layer 21 has a hydrophobic region, the drug contained in the drug-containing resin layer 21 easily migrates from the drug-containing resin layer 21 to the moisture adhering to the upper surface. The drug released from the drug-containing resin layer 21 easily penetrates into the skin together with moisture without returning to the drug-containing resin layer 21.

[0046] The hydrophobic region preferably has a water contact angle of 80° or more as measured by a wettability test. This ensures the hydrophobicity of the hydrophobic region. The water contact angle of the hydrophobic region may be 85° or more, 90° or more, 95° or more, 100° or more, or 102° or more. Although the upper limit of the water contact angle of the hydrophobic region is not particularly limited, it is preferably 120° or less, which facilitates adhesion of moisture to the upper surface 21A of the drug-containing resin layer 21. The water contact angle of the hydrophobic region may be 118° or less, 115° or less, or 110° or less.

[0047] The water contact angle obtained by a wettability test can be measured in accordance with JIS R 3257:1999, and can be measured using a contact angle measuring instrument such as the Mobile Drop DSA series manufactured by Krus. Distilled water is dropped from the microsyringe of the contact angle measuring instrument onto the upper surface 21A of the drug-containing resin layer 21, and the angle between the upper surface 21A of the drug-containing resin layer 21 and the water droplet is read one minute after dropping. The angle can be read by analyzing images captured by a camera such as a high-resolution CCD camera using analysis software.

[0048] The upper surface 21A of the drug-containing resin layer 21 may be entirely hydrophobic, or it may have a hydrophilic region in part. Preferably, a wide area of ​​the upper surface 21A of the drug-containing resin layer 21 is hydrophobic; for example, 50% or more of the upper surface 21A of the drug-containing resin layer 21 is hydrophobic, and it may be 70% or more, 80% or more, or 90% or more. On the upper surface 21A of the drug-containing resin layer 21, the region other than the hydrophobic region can be called the hydrophilic region. The water contact angle in the hydrophilic region is preferably less than 80°, and may be 75° or less, 70° or less, 60° or less, 50° or less, or 40° or less. If the upper surface 21A of the drug-containing resin layer 21 has both hydrophobic and hydrophilic regions, it is preferable to cut out each region and measure the water contact angle.

[0049] If the upper surface 21A of the drug-containing resin layer 21 has a hydrophobic region, a water-permeable sheet 23 may be peelably bonded to the upper surface 21A of the drug-containing resin layer 21, as shown in Figures 5 to 7. Figure 5 shows a cross-sectional view of the adhesive device 1 provided with the water-permeable sheet 23, Figure 6 shows a plan view of the adhesive device 1 shown in Figure 5, and Figure 7 shows a cross-sectional view of the adhesive device 1 shown in Figure 5 in a folded state.

[0050] If the upper surface 21A of the drug-containing resin layer 21 has a hydrophobic region, even if moisture is supplied to the upper surface 21A from the moisture-retaining part 31, the moisture may be repelled on the upper surface 21A, making it difficult for moisture to remain on the upper surface 21A. However, if a water-permeable sheet 23 is provided on the upper surface 21A of the drug-containing resin layer 21, when using the adhesive device 1, the water-permeable sheet 23 is brought into contact with the moisture-retaining part 31, allowing the water-permeable sheet 23 to retain moisture, making it easier for moisture to remain on the upper surface 21A of the drug-containing resin layer 21. After that, the water-permeable sheet 23 is peeled off the upper surface 21A of the drug-containing resin layer 21, thereby attaching the upper surface 21A of the drug-containing resin layer 21 to the skin. By providing the water-permeable sheet 23, the adhesive device 1 makes it easy to attach moisture to the upper surface 21A of the drug-containing resin layer 21 and then attach it to the skin.

[0051] The permeable sheet 23 is not particularly limited as long as it is a sheet that can pass moisture through. Examples of permeable sheet 23 include fabric materials such as nonwoven fabrics, woven fabrics, knitted fabrics, and any sheet material having openings. Among these, the permeable sheet 23 is preferably a perforated sheet or a mesh sheet.

[0052] The perforated sheet is preferably a sheet material with openings formed therein. The material of the perforated sheet is not particularly limited and can be appropriately selected according to the purpose. For example, paper such as glassine paper; resin films made from polyethylene, polyolefin (e.g., polyethylene, polypropylene), polyester (e.g., polyethylene terephthalate), polystyrene, etc.; aluminum foil or aluminum film; foamed resin films such as foamed polyethylene film and foamed polypropylene film can be used. These may be used individually or in combination. The perforated sheet may also be treated with silicone processing, fluororesin processing, embossing, hydrophilic processing, hydrophobic processing, etc. The shape of the opening of the perforated sheet is not particularly limited and can be circular, elliptical, oblong, polygonal, irregular, etc. The size of the opening of the perforated sheet may be, for example, 0.5 mm to 10 mm in diameter.

[0053] A mesh sheet is a sheet in which wires are arranged in a mesh pattern, and at the intersections of the wires arranged in the mesh pattern, the wires may be joined together or not. The wires may be joined together by adhesive or by welding. Yarn is preferably used as the wire. The yarn may be spun yarn or filament yarn, and the filament yarn may be monofilament yarn or multifilament yarn. The size of the mesh openings of the mesh sheet may be, for example, 0.05 mm to 3 mm in terms of the equivalent diameter of a circle.

[0054] The opening ratio of the perforated sheet and mesh sheet may be, for example, 10% to 40%, or 15% to 30%. The opening ratio is determined by measuring the area of ​​each opening formed in the perforated sheet or mesh sheet when the sheet is placed on a flat surface, and dividing this by the area enclosed by the outer edge of the perforated sheet or mesh sheet.

[0055] The permeable sheet 23 preferably covers 50% or more of the upper surface 21A of the drug-containing resin layer 21, and may cover 70% or more, 80% or more, 90% or more, or 100% of the upper surface 21A of the drug-containing resin layer 21. This allows a wider area of ​​the upper surface 21A of the drug-containing resin layer 21 to be wetted with moisture when the permeable sheet 23 is brought into contact with the moisture-retaining part 31. In Figures 5 to 7, the permeable sheet 23 is formed to the same size as the upper surface 21A of the drug-containing resin layer 21.

[0056] As shown in Figure 8, it is preferable that the water-permeable sheet 23 is provided so as to extend beyond the upper surface 21A of the drug-containing resin layer 21. Figure 8 shows a cross-sectional view of another embodiment of the adhesive device 1 provided with the water-permeable sheet 23. In Figure 8, in a plan view of the adhesive device 1, the water-permeable sheet 23 is provided so as to extend beyond the upper surface 21A of the drug-containing resin layer 21. This makes it easy to peel the water-permeable sheet 23 from the upper surface 21A of the drug-containing resin layer 21 after the water-permeable sheet 23 has been brought into contact with the moisture-retaining portion 31 and has retained moisture in the water-permeable sheet 23.

[0057] When attaching the adhesive device 1 to the skin, it is desirable that as much moisture as possible, supplied from the moisture-retaining section 31 and retained in the permeable sheet 23, adheres to the skin surface. From this point of view, when attaching the adhesive device 1 to the skin, it is desirable to have the permeable sheet 23 retain moisture and attach the permeable sheet 23 to the upper surface 21A of the drug-containing resin layer 21, then to face the upper surface 21A of the drug-containing resin layer 21 toward the skin, and in this state, to peel the permeable sheet 23 from the upper surface 21A. At this time, if the permeable sheet 23 protrudes from the upper surface 21A, it becomes easier to peel the permeable sheet 23 from the upper surface 21A while the upper surface 21A of the drug-containing resin layer 21 is facing the skin. Subsequently, by attaching the upper surface 21A of the drug-containing resin layer 21 to the skin, more moisture can be present between the drug-containing resin layer 21 and the skin surface, making the skin surface covered by the drug-containing resin layer 21 more supple and soft.

[0058] It is preferable that the size of the water-permeable sheet 23 is smaller than the size of the moisture-retaining portion 31. Specifically, in a plan view of the adhesive device 1, it is preferable that the size of the water-permeable sheet 23 is smaller than the size of the moisture-retaining portion 31. This makes it easier to bring the entire water-permeable sheet 23 into contact with the moisture-retaining portion 31 when the base sheet 11 is folded back at the folded portion 14, and makes it easier to adhere moisture to a wide area of ​​the water-permeable sheet 23. More preferably, the size of the water-permeable sheet 23 and the drug-containing resin layer 21 are formed to be smaller than the size of the moisture-retaining portion 31.

[0059] As shown in Figure 9, it is also preferable that the water-permeable sheet 23 has a tab 26 that is folded back on the opposite side, i.e., the upper side, from the drug-containing resin layer 21. Figure 9 shows a cross-sectional view of another embodiment of the adhesive device 1 provided with the water-permeable sheet 23. If the water-permeable sheet 23 has a tab 26, it becomes easier to peel the water-permeable sheet 23 from the upper surface 21A of the drug-containing resin layer 21. For example, even if the water-permeable sheet 23 does not protrude from the upper surface 21A, it becomes easier to peel the water-permeable sheet 23 from the upper surface 21A.

[0060] As shown in Figure 10, two or more water-permeable sheets 23 may be provided on the upper surface 21A of the drug-containing resin layer 21. That is, the water-permeable sheet 23 may include a first water-permeable sheet 24 and a second water-permeable sheet 25. Figure 10 shows a cross-sectional view of another embodiment of the adhesive device 1 provided with water-permeable sheets 23. In this case, for example, after the first water-permeable sheet 24 and the second water-permeable sheet 25 have been allowed to retain moisture, one of the first water-permeable sheet 24 and the second water-permeable sheet 25 is peeled off from the upper surface 21A of the drug-containing resin layer 21, and a portion of the upper surface 21A of the drug-containing resin layer 21 is attached to the skin. In that state, the other of the first water-permeable sheet 24 and the second water-permeable sheet 25 is then peeled off from the upper surface 21A of the drug-containing resin layer 21, and the remaining portion of the upper surface 21A of the drug-containing resin layer 21 is attached to the skin. By attaching the drug-containing resin layer 21 to the skin in this way, it becomes easier to create a larger amount of moisture between the drug-containing resin layer 21 and the skin surface.

[0061] Preferably, the first water-permeable sheet 24 and the second water-permeable sheet 25 are laminated on the side of the first water-permeable sheet 24 opposite to the drug-containing resin layer 21, with the first water-permeable sheet 24 being peelably bonded to the upper surface 21A of the drug-containing resin layer 21 and the second water-permeable sheet 25 being peelably bonded to the upper surface 21A of the drug-containing resin layer 21. With the first water-permeable sheet 24 and the second water-permeable sheet 25 provided in this way, it becomes easier to attach the adhesive device 1 to the skin and easier to allow a larger amount of moisture to adhere to the skin surface. In this case, it is preferable that the first water-permeable sheet 24 has a tab that is folded back on the side opposite to the drug-containing resin layer 21, which makes it easier to peel the first water-permeable sheet 24 from the upper surface 21A of the drug-containing resin layer 21. Preferably, the tab portion of the first water-permeable sheet 24 is covered by the second water-permeable sheet 25. This makes it easier to peel off only the second water-permeable sheet 25 without having to grasp the tab portion of the first water-permeable sheet 24 when peeling the second water-permeable sheet 25 from the upper surface 21A of the drug-containing resin layer 21. In this case, the second water-permeable sheet 25 may also have a tab portion that is folded back on the side opposite to the drug-containing resin layer 21.

[0062] As shown in Figure 11, the adhesive device 1 has a water-permeable sheet 23 on the upper surface 21A of the drug-containing resin layer 21, and a support layer 22 is provided on the base sheet 11 side, i.e., the lower side, of the drug-containing resin layer 21, and the support layer 22 may be peelably attached to the base sheet 11. The support layer 22 is handled integrally with the drug-containing resin layer 21, and the drug-containing resin layer 21 can be attached to the skin by peeling the drug-containing resin layer 21 from the base sheet 11 together with the support layer 22.

[0063] The moisture-retaining portion 31 is preferably provided in a recessed area on the first surface 11A of the base sheet 11. That is, it is preferable that a recess 15 is provided on the first surface 11A of the base sheet 11, and the moisture-retaining portion 31 is placed in the recess 15. By placing the moisture-retaining portion 31 in the recess 15 of the first surface 11A of the base sheet 11, moisture can be stably retained in the moisture-retaining portion 31. If the moisture-retaining portion 31 is a porous material or a fiber aggregate in which moisture is retained, it is prevented that the moisture-retaining portion 31 is inadvertently pressed before use of the adhesive device 1, and moisture is stably retained in the porous material or fiber aggregate.

[0064] The recess 15 is formed by recessing the first surface 11A of the base sheet 11. Preferably, the recess 15 is provided in the second region 13 of the base sheet 11. Preferably, the recess 15 in which the moisture-retaining portion 31 is placed is formed only in the second region 13 of the base sheet 11.

[0065] It is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the recess 15. Specifically, in a plan view of the adhesive device 1, it is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the recess 15. This makes it easier to place the entire drug-containing resin layer 21 into the recess 15 when the base sheet 11 is folded back at the folded portion 14, and makes it easier to attach a large amount of moisture to the drug-containing resin layer 21.

[0066] When a water-permeable sheet 23 is provided on the upper surface 21A of the drug-containing resin layer 21, it is preferable that the size of the water-permeable sheet 23 and the drug-containing resin layer 21 are smaller than the size of the recess 15. Specifically, in a plan view of the adhesive device 1, it is preferable that the size of the water-permeable sheet 23 and the drug-containing resin layer 21 are smaller than the size of the recess 15. This allows the entire water-permeable sheet 23 to be placed inside the recess 15 when the base sheet 11 is folded back at the folded portion 14, making it easier for more moisture to adhere to the water-permeable sheet 23.

[0067] When a support layer 22 is provided below the drug-containing resin layer 21, and the support layer 22 is detachably attached to the base sheet 11, and the moisture-retaining portion 31 is provided in a recess 15 on the first surface 11A of the base sheet 11, as shown in Figure 12, a temporary fixing portion 41 may be provided around at least a part of the moisture-retaining portion 31 in the recess 15 of the base sheet 11. In this case, when the base sheet 11 is folded back at the folded portion 14 and the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31, a part of the drug-containing resin layer 21 can be temporarily fixed to the temporary fixing portion 41. After that, by unfolding the folded portion of the base sheet 11, the support layer 22 can be peeled off from the base sheet 11. Furthermore, by peeling the drug-containing resin layer 21 from the temporary fixing portion 41, the drug-containing resin layer 21 can be removed with moisture attached to its upper surface 21A and applied to the skin. In this case, it is preferable that the size of the drug-containing resin layer 21 is larger than the size of the moisture-retaining portion 31.

[0068] The temporary adhesive portion 41, when bonded to the upper surface 21A of the drug-containing resin layer 21, exhibits a peel adhesive strength greater than that between the support layer 22 and the base sheet 11, but less than that between the support layer 22 and the drug-containing resin layer 21. The peel adhesive strength is determined by a 90-degree peel test.

[0069] When a temporary fixing portion 41 is provided in a recess 15 of the first surface 11A of the base sheet 11, it is preferable that the upper surface of the temporary fixing portion 41 is located at a position lower than the upper surface 31A of the moisture-retaining portion 31 by at least half the thickness of the moisture-retaining portion 31. That is, when the lower surface of the moisture-retaining portion 31 is considered 0% and the upper surface 31A of the moisture-retaining portion 31 is considered 100% as relative positions in the thickness direction of the adhesive device 1, it is preferable that the upper surface of the temporary fixing portion 41 is located at a position of 50% or more but less than 100% in the thickness direction of the moisture-retaining portion 31. This makes it easier for the moisture retained in the moisture-retaining portion 31 to adhere to the upper surface 21A of the drug-containing resin layer 21 when the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31 located in the recess 15, and also makes it easier to temporarily fix the upper surface 21A of the drug-containing resin layer 21 to the temporary fixing portion 41. The upper surface of the temporary fastening portion 41 may be located at a position lower than 1 / 3 of the thickness of the moisture-retaining portion 31, 1 / 4 of the thickness, 1 / 20 or more of the thickness, or 1 / 10 or more of the thickness of the moisture-retaining portion 31 than the upper surface 31A of the moisture-retaining portion 31. In other words, the upper surface of the temporary fastening portion 41 may be located at a position between 67% and 95% of the thickness of the moisture-retaining portion 31, or at a position between 75% and 90% of the thickness.

[0070] As described above, since the upper surface of the temporary fastening portion 41 is formed at a certain height from the lower surface of the moisture-retaining portion 31, it is preferable that a base portion 42 is provided in the recess 15 of the base sheet 11 in at least a part of the periphery of the moisture-retaining portion 31, and that the temporary fastening portion 41 is provided on the upper surface of the base portion 42. The temporary fastening portion 41 on the upper surface of the base portion 42 may be formed by appropriately selecting the constituent material of the base portion 42 itself to function as a temporary fastening portion 41, or a sheet material that functions as a temporary fastening portion 41 may be provided on the upper surface of the base portion 42, or the temporary fastening portion 41 may be formed by surface treatment of the upper surface of the base portion 42.

[0071] The temporary fastening portion may be provided in a location other than the recess 15, and may be provided in at least a part of the periphery of the moisture-retaining portion 31 on the first surface 11A of the base sheet 11. In this case, for example, the temporary fastening portion can be formed by providing an adhesive portion in at least a part of the periphery of the moisture-retaining portion 31 on the first surface 11A of the base sheet 11, providing a sheet material different from the base sheet 11, or surface-treating at least a part of the periphery of the moisture-retaining portion 31 on the first surface 11A of the base sheet 11.

[0072] When the base sheet 11 is folded back at the folded portion 14 and the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31, it is preferable that, as shown in Figure 13, the base sheet 11 has a press portion 16 that can be pressed from the second surface 11B side to the first surface 11A side, and the drug-containing resin layer 21 is placed on the press portion 16. With the base sheet 11 configured in this way, when the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31, the press portion 16 of the base sheet 11 can be pressed from the second surface 11B side, thereby strongly pressing the drug-containing resin layer 21 against the moisture-retaining portion 31. This makes it easier to adhere more moisture to the upper surface 21A of the drug-containing resin layer 21.

[0073] The indentation portion 16 can be formed, for example, by folding the base sheet 11. The folded portion of the base sheet 11 becomes movable in the thickness direction, thereby forming the indentation portion 16. Although not shown in the drawings, the indentation portion 16 can also be formed from a bulge portion formed by the base sheet 11 bulging from the first surface 11A to the second surface 11B, and deformable into a shape that bulges from the second surface 11B to the first surface 11A. In this case, by pressing the indentation portion 16 from the second surface 11B, the bulge portion formed by bulging from the first surface 11A to the second surface 11B can be deformed into a shape that bulges from the second surface 11B to the first surface 11A, and the base sheet 11 can be pressed into the indentation portion 16 from the second surface 11B to the first surface 11A.

[0074] As shown in Figure 14, it is preferable that the adhesive device 1 has a release sheet 51 on the first surface 11A side of the base sheet 11. Figure 14 shows a cross-sectional view of another embodiment of the adhesive device 1, which shows an embodiment in which a release sheet 51 is further provided in the adhesive device 1 shown in Figure 1.

[0075] Preferably, the release sheet 51 is laminated on the base sheet 11 such that it covers at least the moisture-retaining portion 31 on the first surface 11A side of the base sheet 11, and the release sheet 51 is peelably bonded to the base sheet 11. This prevents moisture from leaking from the moisture-retaining portion 31 before use of the adhesive device 1. When using the adhesive device 1, the moisture-retaining portion 31 is exposed by peeling the release sheet 51 from the base sheet 11, and the drug-containing resin layer 21 is brought into contact with the moisture-retaining portion 31 by folding the base sheet 11 at the folded portion 14. Preferably, the release sheet 51 is peelably bonded to the base sheet 11 so as to surround the moisture-retaining portion 31.

[0076] It is also preferable that the release sheet 51 is laminated on the base sheet 11 so as to cover the drug-containing resin layer 21 on the first surface 11A side of the base sheet 11. If the upper surface 21A of the drug-containing resin layer 21 is adhesive, providing the release sheet 51 so as to cover the drug-containing resin layer 21 can prevent the drug-containing resin layer 21 from sticking to other components, etc., before use of the adhesive device 1.

[0077] It is more preferable that the release sheet 51 is laminated on the base sheet 11 on the first surface 11A side of the base sheet 11 so as to cover the drug-containing resin layer 21 and the moisture-retaining portion 31, and that the release sheet 51 is peelably bonded to the base sheet 11. This protects the drug-containing resin layer 21 from the release sheet 51 before use of the adhesive device 1 and prevents moisture from leaking from the moisture-retaining portion 31. The release sheet 51 may also be provided on the first surface 11A side of the base sheet 11, overlapping the entire base sheet 11.

[0078] In order for the release sheet 51 to be removably bonded to the base sheet 11, it is preferable that an adhesive layer is provided on the release sheet 51 or the base sheet 11, or that the release sheet 51 and the base sheet 11 are pressed together. The release sheet 51 and the base sheet 11 may also be heat-pressed together. The release sheet 51 may also be removably bonded to the upper surface 21A of the drug-containing resin layer 21.

[0079] As shown in Figure 15, a water-permeable sheet 23 may be provided on the upper surface 21A of the drug-containing resin layer 21, and a release sheet 51 may be provided on the first surface 11A side of the base sheet 11. In this case, it is preferable that the release sheet 51 is laminated on the base sheet 11 on the first surface 11A side of the base sheet 11 so as to cover at least one of the water-permeable sheet 23 and the moisture-retaining portion 31, and that the release sheet 51 is peelably bonded to the base sheet 11. When the release sheet 51 is provided so as to cover the moisture-retaining portion 31, it is preferable that the release sheet 51 is peelably bonded to the base sheet 11 so as to surround the moisture-retaining portion 31. When the release sheet 51 is provided so as to cover the water-permeable sheet 23, it is preferable that the release sheet 51 is not adhered to the water-permeable sheet 23. This prevents the water-permeable sheet 23 from peeling off the upper surface 21A of the drug-containing resin layer 21 when the release sheet 51 is peeled off.

[0080] The material of the release sheet 51 is not particularly limited and can be appropriately selected depending on the purpose. Examples of materials that can be used for the release sheet 51 include paper such as glassine paper; resin films formed from polyolefins (e.g., polyethylene, polypropylene), polyester (e.g., polyethylene terephthalate), polystyrene, etc.; aluminum foil or aluminum film; and foamed resin films such as foamed polyethylene film and foamed polypropylene film. These may be used individually or in combination. The release sheet 51 may also be treated with silicone processing, fluororesin processing, embossing, hydrophilic processing, hydrophobic processing, etc.

[0081] When the base sheet 11 is folded back at the folded portion 14, the base sheet 11 may be provided with a first engaging portion 61 and a second engaging portion 62, as shown in Figures 16 and 17, in order to facilitate the precise alignment and overlap of the drug-containing resin layer 21 with the moisture-retaining portion 31. Figure 16 shows a cross-sectional view of another embodiment of the adhesive device 1, and Figure 17 shows a plan view of the adhesive device 1 shown in Figure 16. Figures 16 and 17 show an embodiment in which the base sheet 11 of the adhesive device 1 shown in Figures 1 and 2 is provided with a first engaging portion 61 and a second engaging portion 62.

[0082] Preferably, the first engaging portion 61 is provided in the first region 12 of the base sheet 11, and the second engaging portion 62 is provided in the second region 13 of the base sheet 11, and the first engaging portion 61 and the second engaging portion 62 are arranged on the base sheet 11 so as to be able to engage with each other by folding the base sheet 11 with the first surface 11A facing inward so that the drug-containing resin layer 21 overlaps the moisture-retaining portion 31. With the base sheet 11 configured in this way, it becomes easy to accurately overlap the drug-containing resin layer 21 onto the moisture-retaining portion 31 by folding the base sheet 11 at the folding portion 14 and engaging the first engaging portion 61 with the second engaging portion 62.

[0083] The first engaging portion 61 and the second engaging portion 62 are not particularly limited as long as they are configured to engage with each other, but it is preferable that they be a combination of a convex portion and a concave portion formed on the first surface 11A of the base sheet 11. The first engaging portion 61 and the second engaging portion 62 can be engaged with each other by folding the base sheet 11 at the folding portion 14 and fitting the convex portion into the concave portion. If the first engaging portion 61 and the second engaging portion 62 are a combination of a convex portion and a concave portion formed on the first surface 11A of the base sheet 11, it is less likely that fingers will be injured even if they come into contact with the first engaging portion 61 and the second engaging portion 62, thereby increasing safety when handling the adhesive device 1.

[0084] The first engaging portion 61 is preferably provided in the first region 12 of the base sheet 11 at a position further away from the folded portion 14 than the drug-containing resin layer 21, and the second engaging portion 62 is preferably provided in the second region 13 of the base sheet 11 at a position further away from the folded portion 14 than the moisture-retaining portion 31. This allows the drug-containing resin layer 21 to be strongly pressed against the moisture-retaining portion 31 when the base sheet 11 is folded at the folded portion 14 and the first engaging portion 61 is engaged with the second engaging portion 62. The number of first engaging portions 61 and second engaging portions 62 may be only one set, or it may be two or more sets. If two or more sets of first engaging portions 61 and second engaging portions 62 are provided, it is preferable that at least one set of first engaging portions 61 and second engaging portions 62 are provided as described above.

[0085] The adhesive device 1 can be used by placing it on epithelial tissue. The epithelial tissue on which the adhesive device 1 is placed may be epithelial tissue of the skin or epithelial tissue of the mucous membrane, but it is preferable that it be epithelial tissue of the skin. The adhesive device 1 is preferably placed on human epithelial tissue, but it may also be placed on the epithelial tissue of animals other than humans, such as dogs, cats, horses, and cattle.

[0086] Although various embodiments of the adhesive device according to this disclosure have been described above, each configuration of the adhesive device described above can be implemented by arbitrarily combining or substituting multiple embodiments. For example, the configurations relating to the support layer, water-permeable sheet, release sheet, temporary fastening portion, pressing portion, and first and second engaging portions can be applied to any of the embodiments described above.

[0087] This application claims the benefit of priority based on Japanese Patent Applications No. 2025-052032 and No. 2025-052034, filed on 26 March 2025. The entire contents of the specifications of Japanese Patent Applications No. 2025-052032 and No. 2025-052034, filed on 26 March 2025, are incorporated herein by reference.

[0088] 1: Adhesive device 11: Base sheet, 11A: First surface, 11B: Second surface 12: First region 13: Second region 14: Folded portion 15: Recess 16: Press-in portion 21: Drug-containing resin layer, 21A: Top surface 22: Support layer 23: Water-permeable sheet 24: First water-permeable sheet 25: Second water-permeable sheet 26: Pinching portion 31: Moisture-retaining portion, 31A: Top surface 41: Temporary fastening portion 42: Base portion 51: Release sheet 61: First engaging portion 62: Second engaging portion

Claims

1. An adhesive device comprising: a base sheet having a first surface and a second surface; a drug-containing resin layer provided on the first surface of the base sheet; and a moisture-retaining portion provided on the first surface of the base sheet, wherein the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet such that the drug-containing resin layer overlaps the moisture-retaining portion when the base sheet is folded back with the first surface facing inward between the drug-containing resin layer and the moisture-retaining portion.

2. The adhesive device according to claim 1, wherein the side of the drug-containing resin layer opposite to the base sheet is adhesive.

3. The adhesive device according to claim 1, wherein the surface of the drug-containing resin layer opposite to the base sheet has a hydrophobic region.

4. The adhesive device according to claim 1, wherein a valley fold line is formed on the first surface of the base sheet, and the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet such that the drug-containing resin layer overlaps the moisture-retaining portion by folding the base sheet back along the valley fold line with the first surface facing inward.

5. The adhesive device according to claim 1, wherein perforations are formed on the first surface of the base sheet, and the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet such that the drug-containing resin layer overlaps the moisture-retaining portion by folding the base sheet back along the perforations with the first surface facing inward.

6. The adhesive device according to claim 1, wherein a support layer is provided on the base sheet side of the drug-containing resin layer, and the support layer is peelably attached to the base sheet.

7. The adhesive device according to claim 1, wherein a recess is provided on the first surface of the base sheet, and the moisture-retaining portion is arranged in the recess.

8. The adhesive device according to claim 7, wherein the size of the drug-containing resin layer is smaller than the size of the moisture-retaining portion.

9. The adhesive device according to claim 1, wherein a support layer is provided on the base sheet side of the drug-containing resin layer, the support layer is peelably attached to the base sheet, a recess is provided on the first surface of the base sheet, the recess is provided with the moisture-retaining portion and a temporary fixing portion of the drug-containing resin layer is provided in at least a part of the periphery of the moisture-retaining portion, and the upper surface of the temporary fixing portion is located at a position lower than or equal to half the thickness of the moisture-retaining portion than the upper surface of the moisture-retaining portion.

10. The adhesive device according to any one of claims 7 to 9, wherein the base sheet has a pressable portion formed therein that can be pressed from the second surface to the first surface, and the drug-containing resin layer is disposed in the pressable portion.

11. The adhesive device according to claim 1, wherein the moisture-retaining portion is a porous body that retains moisture or a fiber aggregate that retains moisture.

12. The adhesive device according to claim 1, further comprising a release sheet laminated on the base sheet so as to cover the drug-containing resin layer and the moisture-retaining portion on the first surface side of the base sheet, wherein the release sheet is peelably bonded to the base sheet.

13. The adhesive device according to claim 1, wherein the first surface of the base sheet is divided into a first region and a second region, the drug-containing resin layer is provided in the first region, the moisture-retaining portion is provided in the second region, a first engaging portion is provided in the first region of the base sheet, a second engaging portion is provided in the second region of the base sheet, and the first engaging portion and the second engaging portion are arranged on the base sheet so as to be able to engage with each other by folding the base sheet with the first surface facing inward and the drug-containing resin layer overlapping the moisture-retaining portion.

14. The adhesive device according to claim 13, wherein the first engaging portion and the second engaging portion are a combination of a convex portion and a concave portion formed on the first surface of the base sheet.

15. The adhesive device according to claim 3, further comprising a water-permeable sheet peelably bonded to the surface of the drug-containing resin layer opposite to the base sheet.

16. The adhesive device according to claim 15, wherein the drug-containing resin layer and the moisture-retaining portion are arranged on the base sheet by folding the base sheet with the first surface facing inward between the drug-containing resin layer and the moisture-retaining portion, so that the water-permeable sheet overlaps the moisture-retaining portion.

17. The adhesive device according to claim 15, further comprising a release sheet, wherein the release sheet is provided to cover at least one of the water-permeable sheet and the moisture-retaining portion.

Images